| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13D/A | 2024-04-25 | AUVEN THERAPEUTICS HOLDINGS LP | ADC Therapeutics SA | 2,231,210 | 2.7% | EDGAR |
| SC 13G/A | 2024-02-14 | Redmile Group, LLC | ADC Therapeutics SA | 15,328,317 | 18.8% | EDGAR |
| SC 13G/A | 2024-02-13 | Prosight Management, LP | ADC Therapeutics SA | 6,471,800 | 8.0% | EDGAR |
| SC 13G/A | 2024-02-12 | ASTRAZENECA PLC | ADC Therapeutics SA | 4,011,215 | 4.9% | EDGAR |
| SC 13D/A | 2023-04-28 | AUVEN THERAPEUTICS HOLDINGS LP | ADC Therapeutics SA | 6,330,548 | 7.9% | EDGAR |
| SC 13G | 2023-04-17 | Prosight Management, LP | ADC Therapeutics SA | 4,304,518 | 5.3% | EDGAR |
| SC 13G/A | 2023-04-10 | FMR LLC | ADC Therapeutics SA | 40,444 | 0.1% | EDGAR |
| SC 13G/A | 2023-02-10 | Redmile Group, LLC | ADC Therapeutics SA | 13,565,249 | 16.8% | EDGAR |
| SC 13G/A | 2023-02-09 | FMR LLC | ADC Therapeutics SA | 4,653,453 | 6.0% | EDGAR |
| SC 13D/A | 2023-02-06 | AUVEN THERAPEUTICS HOLDINGS LP | ADC Therapeutics SA | 6,330,548 | 7.9% | EDGAR |
| SC 13D/A | 2022-12-23 | AUVEN THERAPEUTICS HOLDINGS LP | ADC Therapeutics SA | 18,330,548 | 23.8% | EDGAR |
| SC 13D/A | 2022-12-09 | AUVEN THERAPEUTICS HOLDINGS LP | ADC Therapeutics SA | 18,330,548 | 23.8% | EDGAR |
| SC 13D/A | 2022-12-08 | AUVEN THERAPEUTICS HOLDINGS LP | ADC Therapeutics SA | 21,418,730 | 27.8% | EDGAR |
| SC 13G/A | 2022-02-14 | Redmile Group, LLC | ADC Therapeutics SA | 7,451,029 | 9.7% | EDGAR |
| SC 13G/A | 2022-02-09 | FMR LLC | ADC Therapeutics SA | 7,672,673 | 10.0% | EDGAR |
| SC 13G/A | 2021-04-12 | FMR LLC | ADC Therapeutics SA | 7,761,585 | 10.1% | EDGAR |
| SC 13G | 2021-02-16 | Redmile Group, LLC | ADC Therapeutics SA | 6,758,794 | 8.8% | EDGAR |
| SC 13G | 2021-02-10 | ASTRAZENECA PLC | ADC Therapeutics SA | 4,011,215 | 5.2% | EDGAR |
| SC 13G/A | 2021-02-08 | FMR LLC | ADC Therapeutics SA | 7,761,585 | 10.0% | EDGAR |
| SC 13G | 2020-12-10 | FMR LLC | ADC Therapeutics SA | 7,761,733 | 10.0% | EDGAR |